Allarity Therapeutics Inc (ALLR) Stock AnalysisALLRAllarity Therapeutics Inc

Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing personalized cancer treatments. It is focused on development of stenoparib, a PARP/tankyrase inhibitor for advanced ovarian cancer patients, using its DRP technology to develop a companion diagnostic that can be used to select those patients expected to derive clinical benefit from stenoparib. Its therapeutic candidate, stenoparib, is a dual inhibitor of the key DNA damage repair enzyme PARP, as well as Tankyrases, critical enzymes involved in the WNT signaling pathway commonly activated in many cancers. Inhibition of key DNA damage repair enzymes, such as PARP, has clinically demonstrated to be therapeutically beneficial in the treatment of cancers (ovarian cancers). The DRP method builds on the comparison of sensitive vs. resistant human cancer cell lines, including transcriptomic information from cell lines, combined with clinical tumor biology filters and prior clinical trial outcomes. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Allarity Therapeutics is a good buy right now, with a current price of $1.41 and a recent RSI of 60.89 indicating bullish momentum. The stock has shown a year-to-date change of +23.68%, reflecting positive market sentiment. However, the main risk is its significant net loss of $3.4 million in Q2 2026, which highlights ongoing financial challenges that investors should consider.